论文部分内容阅读
目的探讨腹腔热化疗治疗卵巢癌合并腹水的疗效及毒副反应。方法将入选病例随机分为两组,治疗组采用腹腔热疗联合腹腔灌注化疗;对照组则仅行腹腔灌注化疗,剂量与治疗组相同,未进行腹腔热疗。结果治疗组卵巢肿瘤治疗总有效率60.5%(23/38),对照组为28.6%(10/35),两组比较差异有显著性(P<0.05);治疗组腹水治疗总有效率84.2%(32/38),对照组为57.1%(20/35),两组比较差异有显著性(P<0.05)。而两组患者治疗前后T淋巴细胞亚群结果比较,差异有显著性(P<0.05)。毒副反应主要为胃肠道反应、骨髓抑制及腹痛,两组毒副反应比较,差异无显著性(P>0.05)。结论热疗联合化疗药物腹腔灌注治疗卵巢癌合并腹水具有协同效应,增强抗癌效果、提高免疫力并抑制肿瘤细胞活性,治疗毒副反应可耐受。
Objective To investigate the efficacy and side effects of intraperitoneal hyperthermia in the treatment of ovarian cancer with ascites. Methods The selected cases were randomly divided into two groups. The treatment group received intraperitoneal hyperthermia combined with intraperitoneal perfusion chemotherapy. The control group received intraperitoneal chemotherapy only. The dose was the same as that of the treatment group, and no intraperitoneal hyperthermia was performed. Results The total effective rate of treatment for ovarian cancer was 60.5% (23/38) in the treatment group and 28.6% (10/35) in the control group, with significant difference between the two groups (P <0.05). The treatment group had a total effective rate of 84.2% (32/38) in the control group and 57.1% (20/35) in the control group. There was significant difference between the two groups (P <0.05). There was significant difference between the two groups before and after T lymphocyte subsets (P <0.05). Toxic and side effects mainly gastrointestinal reactions, bone marrow suppression and abdominal pain, the two groups of side effects, no significant difference (P> 0.05). Conclusion Hyperthermia combined with chemotherapy drugs peritoneal perfusion treatment of ovarian cancer combined with ascites has a synergistic effect, enhance anti-cancer effect, improve immunity and inhibit tumor cell activity, the treatment of toxic and side effects can be tolerated.